In recent years, there has been a surge of new technologies for cancer treatment such as molecular targeted therapies (i.e., anti-tyrosine kinase and anti-HER2) [1], immunotherapies such as cancer vaccines or anti-PD1 [2,3], sophisticated radiation therapy [4], and advanced tumor-targeting technologies such as nanoparticles and antibody–drug conjugates. This evidence concerns the gene ERBB2 and cancer.